Saluda Medical Unveils EVA™ Sensing Technology
Saluda Medical, renowned for its pioneering work in neuromodulation, has joyfully announced the full U.S. launch of its groundbreaking EVA™ Sensing Technology. Designed to work seamlessly with the Evoke® SmartLoop™ System, EVA aims to enhance the quality of life for patients suffering from chronic neurological conditions. This launch is particularly significant as it follows the FDA's approval in December 2024, marking a pivotal moment in medical technology.
What is EVA?
EVA represents a substantial leap forward in spinal cord stimulation (SCS) therapy. This innovative technology employs advanced algorithms to objectively scan the spinal cord, analyzing real-time neural responses. By utilizing this data, EVA personalizes treatment, delivering precise therapy levels that exceed human capabilities. Patients with implanted Evoke SmartLoop Systems will now benefit from this enhanced form of stimulation management, significantly improving pain relief and therapeutic effectiveness.
Mike Mathias, Saluda Medical’s Chief Commercial Officer, stated, “The full launch of EVA is a remarkable advancement in SCS therapy. It promises objective dosing, which translates to more effective pain management for patients. Moreover, EVA alleviates the manual programming steps traditionally involved, enhancing the patient experience.” This automation not only streamlines processes but optimizes the overall efficacy of treatments.
Early Success and Clinical Evidence
Since the limited market release of EVA, it has already participated in over 3,000 patient visits. The forthcoming ASPN 2025 Annual Conference will showcase new clinical data supporting EVA's effectiveness. With 11 abstracts and an oral presentation planned for the July 17-20 event in Miami, these findings will contribute to Saluda's growing portfolio of over 37 clinical publications.
As Dr. Jason Pope, Founder and CEO of Evolve Restorative Center, expressed, “The Evoke SmartLoop System equipped with EVA facilitates objective dosing capabilities that lead to better and longer-lasting outcomes in SCS therapy.” He emphasized the growing body of evidence further validating EVA's superior functionality, especially in maintaining therapy response over time without any decline in efficacy.
The Impact of Saluda Medical
As a commercially-driven medical device enterprise, Saluda Medical focuses on developing cutting-edge treatments for chronic neurological challenges. The company relies on its closed-loop, dose-control platform that assesses and reacts to neural activity, ensuring continual adjustments are made to enhance therapy. The Evoke System, Saluda's flagship product, is pivotal in managing complex pain conditions associated with failed back surgeries, chronic low back pain, and neuropathic issues.
Noteworthy landmarks from their EVOKE Study—a leading prospective, multi-center, randomized controlled trial—have showcased the long-term effectiveness of the Evoke System. These results, which have been featured in esteemed publications like The Lancet Neurology and JAMA Neurology, establish a solid foundation for the credibility of their technologies.
Conclusion
The official launch of EVA Sensing Technology signifies not just a new chapter for Saluda Medical but a transformative moment for those living with chronic pain. With promising clinical outcomes and the commitment to improving patient experiences, Saluda Medical stands at the forefront of innovation in neuromodulation therapy. For further information—including details about risks and other essential safety information—please visit
Saluda Medical's website.